Format

Send to

Choose Destination
Future Microbiol. 2011 May;6(5):495-511. doi: 10.2217/fmb.11.30.

Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter.

Author information

1
Department of Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, CRESIB, IDIBAPS, Spain.

Abstract

Species of Acinetobacter other than Acinetobacter baumannii are involved in nosocomial infections. Acinetobacter lwoffii, Acinetobacter genomospecies 3 and Acinetobacter genomospecies 13TU are found in community- and nosocomial-acquired infections as well as in neonatal intensive care units. The non-baumannii Acinetobacter are normally highly susceptible to ciprofloxacin, ampicillin/sulbactam, gentamicin and tigecycline. Carbepenems show good activity although resistant isolates have been reported. Resistance to β-lactams other than carbapenems is associated with overexpression of chromosomal cephalosporinases and extended-spectrum β-lactamase acquisition, whereas resistance to carbapenems involves acquisition of carbapenemases. Quinolone resistance is related to gyrA and/or parC mutations but overexpresion of efflux proteins also plays an important role. With the development of novel and more accurate typing methodologies, an increase in infections caused by non-baumannii Acinetobacter might be observed in the future.

PMID:
21585259
DOI:
10.2217/fmb.11.30
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center